Conclusions
Thromboembolic events were seen despite the anticoagulant prophylaxis in
our study. Development of thrombosis were associated with
hyperinflammation in patients with severe and critical COVID-19.
Intravenous high-dose anakinra treatment decreases both venous and
arterial events in patients with COVID-19.
Acknowledgments: Many thanks to Prof. Ahmet Gül for shedding
ligh of our way.